All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-5875
Request that the FDA grant permission to file an abbreviated new animal drug application (ANADA) for a generic soft chewable tablet for Graphiprant that differs from the pioneer product Galliprant (grapiprant tablets), sponsored by Elanco US Inc, under NADA 141-455
Documents
4
Comments
0
Description
OPEN
Key Dates
Comment Period OpensMay 21, 2026
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CVM
Suitability Petition
Felix Pharmaceuticals Pvt. Ltd.
grant permission to file an abbreviated
new animal drug application (ANADA)
for a generic soft chewable tablet for
Graphiprant that differs from the pioneer
product Galliprant (grapiprant tablets),
Data from Regulations.gov